An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, multi-center, double-blind, randomized, placebo-controlled,
dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and
immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all
clinical presentations of MS.